{"protocolSection":{"identificationModule":{"nctId":"NCT00413283","orgStudyIdInfo":{"id":"20050154"},"organization":{"fullName":"Amgen","class":"INDUSTRY"},"briefTitle":"Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"Phase 2, Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 For Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Advanced Non-Small Cell Lung Cancer Already Receiving Gemcitabine and Platinum."},"statusModule":{"statusVerifiedDate":"2013-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-12"},"primaryCompletionDateStruct":{"date":"2008-12","type":"ACTUAL"},"completionDateStruct":{"date":"2009-02","type":"ACTUAL"},"studyFirstSubmitDate":"2006-12-15","studyFirstSubmitQcDate":"2006-12-15","studyFirstPostDateStruct":{"date":"2006-12-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-09-24","resultsFirstSubmitQcDate":"2010-09-24","resultsFirstPostDateStruct":{"date":"2010-10-21","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-09-18","lastUpdatePostDateStruct":{"date":"2013-10-24","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Amgen","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum."},"conditionsModule":{"conditions":["Lung Cancer","Chemotherapy-Induced Thrombocytopenia","Non-Small Cell Lung Cancer","Cancer","Lung Neoplasms","Oncology","Solid Tumors","Thrombocytopenia"],"keywords":["Advanced Non-Small Cell Lung Cancer","Chemotherapy Induced Thrombocytopenia","CIT","NSCLC","Stage IIIB NSCLC","Stage IV NSCLC","Gemcitabine","Carboplatin","Cisplatin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"SUPPORTIVE_CARE","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":63,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.","interventionNames":["Drug: Placebo","Drug: Gemcitabine","Drug: Carboplatin","Drug: Cisplatin"]},{"label":"Romiplostim 250 μg","type":"EXPERIMENTAL","description":"Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.","interventionNames":["Biological: Romiplostim","Drug: Gemcitabine","Drug: Carboplatin","Drug: Cisplatin"]},{"label":"Romiplostim 500 μg","type":"EXPERIMENTAL","description":"Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.","interventionNames":["Biological: Romiplostim","Drug: Gemcitabine","Drug: Carboplatin","Drug: Cisplatin"]},{"label":"Romiplostim 750 μg","type":"EXPERIMENTAL","description":"Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.","interventionNames":["Biological: Romiplostim","Drug: Gemcitabine","Drug: Carboplatin","Drug: Cisplatin"]}],"interventions":[{"type":"BIOLOGICAL","name":"Romiplostim","description":"Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.","armGroupLabels":["Romiplostim 250 μg","Romiplostim 500 μg","Romiplostim 750 μg"],"otherNames":["AMG 531","Nplate®"]},{"type":"DRUG","name":"Placebo","description":"Placebo subcutaneous injection.","armGroupLabels":["Placebo"]},{"type":"DRUG","name":"Gemcitabine","description":"Intravenous infusion","armGroupLabels":["Placebo","Romiplostim 250 μg","Romiplostim 500 μg","Romiplostim 750 μg"]},{"type":"DRUG","name":"Carboplatin","description":"Intravenous infusion","armGroupLabels":["Placebo","Romiplostim 250 μg","Romiplostim 500 μg","Romiplostim 750 μg"]},{"type":"DRUG","name":"Cisplatin","description":"Intravenous infusion","armGroupLabels":["Placebo","Romiplostim 250 μg","Romiplostim 500 μg","Romiplostim 750 μg"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Adverse Events","description":"This summary includes all treatment-emergent adverse events recorded from the start of investigational product on this study, or any worsening of adverse events initially experienced before initiation of this study.","timeFrame":"4 months"}],"secondaryOutcomes":[{"measure":"Duration of Grade 3 or 4 Thrombocytopenia","description":"The duration of grade 3 or 4 thrombocytopenia (defined as platelet count \\<50 x 10\\^9/L) experienced during the first on study chemotherapy cycle by treatment group.","timeFrame":"3 weeks"},{"measure":"Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle.","description":"The number of participants in each treatment group with grade 3 or 4 thrombocytopenia during the first on study treatment cycle. Per the Common Terminology Criteria for Adverse Events (CTCAE) v3.0, participants with a platelet count \\< 50 x 10\\^9/L, but ≥ 25 x 10\\^9/L are considered to have Grade 3 thrombocytopenia and participants with a platelet count \\< 25 x 10\\^9/L are considered to have Grade 4 thrombocytopenia. Additionally, participants with a platelet transfusion during the first on-study treatment cycle were classified as having Grade 3/4 thrombocytopenia.","timeFrame":"3 weeks"},{"measure":"Number of Participants With Platelet Transfusions","description":"Number of participants who were administered platelet transfusions during first on study treatment cycle.","timeFrame":"3 weeks"},{"measure":"Platelet Count on Day 22","description":"Platelet count on Day 22 of the first on study chemotherapy treatment cycle (planned Day 1 of next cycle) by treatment group","timeFrame":"Day 22"},{"measure":"Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle","description":"Number of participants who required a gemcitabine dose reduction on Day 8 of the first on study chemotherapy cycle.","timeFrame":"8 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced or metastatic stage IIIB or stage IV NSCLC receiving 21-day cycles of gemcitabine/carboplatin or gemcitabine/cisplatin\n* Life expectancy ≥ 12 weeks at the time of screening\n* Thrombocytopenia as evidenced by a platelet count ≤ 50 x 10\\^9/L during the qualifying cycle of chemotherapy, OR platelet count \\< 100 x 10\\^9/L on Day 22 of the qualifying cycle (for eligibility inclusion: ability to receive the same dose of chemotherapy on study), this criteria ensures that the patient must be dose delayed for platelet recovery\n* Ability to receive the same dose and schedule of chemotherapy during the first on-study treatment cycle as was given in the qualifying cycle (except Day 8 gemcitabine)\n* Absolute neutrophil count (ANC) ≥ 1,000/µL, hemoglobin ≥ 9.5 g/dL, and platelet count ≥ 100 x 10 \\^9/L on Day 1 of the first on study chemotherapy treatment cycle\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at the time of screening\n* Adequate Liver function; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\< 3.0 x upper limit of normal (ULN) (except for patients with a confirmed diagnosis of Gilbert's Syndrome)\n* Adequate renal function; serum creatinine \\< 1.5 x ULN\n\nExclusion Criteria:\n\n* Receipt of \\> 1 prior systemic chemotherapy regimen\n* Sepsis, disseminated coagulation or any other condition (i.e. immune \\[idiopathic\\] thrombocytopenic purpura \\[ITP\\], thrombotic thrombocytopenic purpura \\[TTP\\], hemolytic uremic syndrome \\[HUS\\]) that may exacerbate thrombocytopenia\n* History of unstable angina, congestive heart failure, uncontrolled hypertension (diastolic \\> 100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year of screening ) myocardial infarction\n* History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 1 year of screening\n* History of pulmonary embolism or other venous thrombosis within 1 year of screening (except for catheter-related clots)\n* Use of any nitrosourea or mitomycin-C within 6 weeks of screening\n* Have received any thrombopoietic growth factor or related substance\n* Have received granulocyte macrophage colony stimulating factor (GM-CSF) within the last 4 weeks prior to screening\n* Have received any experimental therapy within 4 weeks prior to screening\n* Have ever received a bone marrow or peripheral blood stem cell infusion (within 1 year of screening)\n* Known hypersensitivity to any recombinant E. coli-derived product.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"MD","affiliation":"Amgen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Glendale","state":"Arizona","zip":"85304","country":"United States","geoPoint":{"lat":33.53865,"lon":-112.18599}},{"facility":"Research Site","city":"Glendale","state":"Arizona","country":"United States","geoPoint":{"lat":33.53865,"lon":-112.18599}},{"facility":"Research Site","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Research Site","city":"Anaheim","state":"California","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Research Site","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Research Site","city":"Los Angeles","state":"California","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Research Site","city":"Rancho Mirage","state":"California","zip":"92270","country":"United States","geoPoint":{"lat":33.73974,"lon":-116.41279}},{"facility":"Research Site","city":"Rancho Mirage","state":"California","country":"United States","geoPoint":{"lat":33.73974,"lon":-116.41279}},{"facility":"Research Site","city":"Boynton Beach","state":"Florida","zip":"33435","country":"United States","geoPoint":{"lat":26.52535,"lon":-80.06643}},{"facility":"Research Site","city":"Boynton Beach","state":"Florida","country":"United States","geoPoint":{"lat":26.52535,"lon":-80.06643}},{"facility":"Research Site","city":"Vero Beach","state":"Florida","zip":"32960","country":"United States","geoPoint":{"lat":27.63864,"lon":-80.39727}},{"facility":"Research Site","city":"Vero Beach","state":"Florida","country":"United States","geoPoint":{"lat":27.63864,"lon":-80.39727}},{"facility":"Research Site","city":"Athens","state":"Georgia","zip":"30607","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"Research Site","city":"Athens","state":"Georgia","country":"United States","geoPoint":{"lat":33.96095,"lon":-83.37794}},{"facility":"Research Site","city":"Macon","state":"Georgia","zip":"31201","country":"United States","geoPoint":{"lat":32.84069,"lon":-83.6324}},{"facility":"Research Site","city":"Macon","state":"Georgia","country":"United States","geoPoint":{"lat":32.84069,"lon":-83.6324}},{"facility":"Research Site","city":"Peoria","state":"Illinois","zip":"61615","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Research Site","city":"Peoria","state":"Illinois","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Research Site","city":"Sioux City","state":"Iowa","zip":"51101","country":"United States","geoPoint":{"lat":42.49999,"lon":-96.40031}},{"facility":"Research Site","city":"Sioux City","state":"Iowa","country":"United States","geoPoint":{"lat":42.49999,"lon":-96.40031}},{"facility":"Research Site","city":"Paducah","state":"Kentucky","zip":"42003","country":"United States","geoPoint":{"lat":37.08339,"lon":-88.60005}},{"facility":"Research Site","city":"Paducah","state":"Kentucky","country":"United States","geoPoint":{"lat":37.08339,"lon":-88.60005}},{"facility":"Research Site","city":"Shreveport","state":"Louisiana","zip":"71101","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Research Site","city":"Shreveport","state":"Louisiana","country":"United States","geoPoint":{"lat":32.52515,"lon":-93.75018}},{"facility":"Research Site","city":"Baltimore","state":"Maryland","zip":"21201","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Research Site","city":"Baltimore","state":"Maryland","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Research Site","city":"Sterling Heights","state":"Michigan","zip":"48314","country":"United States","geoPoint":{"lat":42.58031,"lon":-83.0302}},{"facility":"Research Site","city":"Sterling Heights","state":"Michigan","country":"United States","geoPoint":{"lat":42.58031,"lon":-83.0302}},{"facility":"Research Site","city":"Billings","state":"Montana","zip":"59101","country":"United States","geoPoint":{"lat":45.78329,"lon":-108.50069}},{"facility":"Research Site","city":"Billings","state":"Montana","country":"United States","geoPoint":{"lat":45.78329,"lon":-108.50069}},{"facility":"Research Site","city":"Flemington","state":"New Jersey","zip":"08822","country":"United States","geoPoint":{"lat":40.51233,"lon":-74.85933}},{"facility":"Research Site","city":"Flemington","state":"New Jersey","country":"United States","geoPoint":{"lat":40.51233,"lon":-74.85933}},{"facility":"Research Site","city":"Johnson City","state":"New York","zip":"13790","country":"United States","geoPoint":{"lat":42.11563,"lon":-75.95881}},{"facility":"Research Site","city":"Johnson City","state":"New York","country":"United States","geoPoint":{"lat":42.11563,"lon":-75.95881}},{"facility":"Research Site","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Research Site","city":"Oklahoma City","state":"Oklahoma","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Research Site","city":"Drexel Hill","state":"Pennsylvania","zip":"19026","country":"United States","geoPoint":{"lat":39.94706,"lon":-75.29213}},{"facility":"Research Site","city":"Drexel Hill","state":"Pennsylvania","country":"United States","geoPoint":{"lat":39.94706,"lon":-75.29213}},{"facility":"Research Site","city":"Dunmore","state":"Pennsylvania","zip":"18512","country":"United States","geoPoint":{"lat":41.4198,"lon":-75.63241}},{"facility":"Research Site","city":"Dunmore","state":"Pennsylvania","country":"United States","geoPoint":{"lat":41.4198,"lon":-75.63241}},{"facility":"Research Site","city":"Radnor","state":"Pennsylvania","zip":"19087","country":"United States","geoPoint":{"lat":40.04622,"lon":-75.35991}},{"facility":"Research Site","city":"Radnor","state":"Pennsylvania","country":"United States","geoPoint":{"lat":40.04622,"lon":-75.35991}},{"facility":"Research Site","city":"Columbia","state":"South Carolina","zip":"29203","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"Research Site","city":"Columbia","state":"South Carolina","country":"United States","geoPoint":{"lat":34.00071,"lon":-81.03481}},{"facility":"Research Site","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"Research Site","city":"Germantown","state":"Tennessee","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"Research Site","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Research Site","city":"Austin","state":"Texas","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Research Site","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Site","city":"Houston","state":"Texas","zip":"77074","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Site","city":"Houston","state":"Texas","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Site","city":"Graz","zip":"8036","country":"Austria","geoPoint":{"lat":47.06733,"lon":15.44197}},{"facility":"Research Site","city":"Graz","country":"Austria","geoPoint":{"lat":47.06733,"lon":15.44197}},{"facility":"Research Site","city":"Innsbruck","zip":"6020","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"facility":"Research Site","city":"Innsbruck","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"facility":"Research Site","city":"Klagenfurt","zip":"9026","country":"Austria","geoPoint":{"lat":46.62472,"lon":14.30528}},{"facility":"Research Site","city":"Klagenfurt","country":"Austria","geoPoint":{"lat":46.62472,"lon":14.30528}},{"facility":"Research Site","city":"Linz","zip":"4010","country":"Austria","geoPoint":{"lat":48.30639,"lon":14.28611}},{"facility":"Research Site","city":"Linz","country":"Austria","geoPoint":{"lat":48.30639,"lon":14.28611}},{"facility":"Research Site","city":"Rankweil","zip":"6830","country":"Austria","geoPoint":{"lat":47.27108,"lon":9.64308}},{"facility":"Research Site","city":"Rankweil","country":"Austria","geoPoint":{"lat":47.27108,"lon":9.64308}},{"facility":"Research Site","city":"Vienna","zip":"1090","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Research Site","city":"Vienna","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"Research Site","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Research Site","city":"Toronto","state":"Ontario","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Research Site","city":"Sainte-Foy","state":"Quebec","zip":"G1V 4G5","country":"Canada","geoPoint":{"lat":46.78139,"lon":-71.29217}},{"facility":"Research Site","city":"Sainte-Foy","state":"Quebec","country":"Canada","geoPoint":{"lat":46.78139,"lon":-71.29217}},{"facility":"Research Site","city":"Bad Berka","zip":"99437","country":"Germany","geoPoint":{"lat":50.89982,"lon":11.28245}},{"facility":"Research Site","city":"Bad Berka","country":"Germany","geoPoint":{"lat":50.89982,"lon":11.28245}},{"facility":"Research Site","city":"Dresden","zip":"01307","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Research Site","city":"Dresden","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Research Site","city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"Research Site","city":"Halle","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"Research Site","city":"Hemer","zip":"58675","country":"Germany","geoPoint":{"lat":51.38707,"lon":7.77019}},{"facility":"Research Site","city":"Hemer","country":"Germany","geoPoint":{"lat":51.38707,"lon":7.77019}},{"facility":"Research Site","city":"Budapest","zip":"1125","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Budapest","zip":"1529","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Budapest","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Research Site","city":"Edelény","zip":"3780","country":"Hungary","geoPoint":{"lat":48.3,"lon":20.73333}},{"facility":"Research Site","city":"Edelény","country":"Hungary","geoPoint":{"lat":48.3,"lon":20.73333}},{"facility":"Research Site","city":"Gyula","zip":"5703","country":"Hungary","geoPoint":{"lat":46.65,"lon":21.28333}},{"facility":"Research Site","city":"Gyula","country":"Hungary","geoPoint":{"lat":46.65,"lon":21.28333}},{"facility":"Research Site","city":"Mátraháza","zip":"3233","country":"Hungary","geoPoint":{"lat":47.87124,"lon":19.97981}},{"facility":"Research Site","city":"Mátraháza","country":"Hungary","geoPoint":{"lat":47.87124,"lon":19.97981}},{"facility":"Research Site","city":"Pécs","zip":"7623","country":"Hungary","geoPoint":{"lat":46.07617,"lon":18.22814}},{"facility":"Research Site","city":"Pécs","country":"Hungary","geoPoint":{"lat":46.07617,"lon":18.22814}},{"facility":"Research Site","city":"Székesfehérvár","zip":"8000","country":"Hungary","geoPoint":{"lat":47.18995,"lon":18.41034}},{"facility":"Research Site","city":"Székesfehérvár","country":"Hungary","geoPoint":{"lat":47.18995,"lon":18.41034}},{"facility":"Research Site","city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"Research Site","city":"Törökbálint","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"Research Site","city":"Zalaegerszeg - Pozva","zip":"8900","country":"Hungary"},{"facility":"Research Site","city":"Zalaegerszeg - Pozva","country":"Hungary"},{"facility":"Research Site","city":"Cork","zip":"Cork","country":"Ireland","geoPoint":{"lat":51.89797,"lon":-8.47061}},{"facility":"Research Site","city":"Cork","country":"Ireland","geoPoint":{"lat":51.89797,"lon":-8.47061}},{"facility":"Research Site","city":"Dublin","zip":"4","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Research Site","city":"Dublin","zip":"8","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Research Site","city":"Dublin","country":"Ireland","geoPoint":{"lat":53.33306,"lon":-6.24889}},{"facility":"Research Site","city":"Novara","zip":"28100","country":"Italy","geoPoint":{"lat":45.44694,"lon":8.62118}},{"facility":"Research Site","city":"Novara","country":"Italy","geoPoint":{"lat":45.44694,"lon":8.62118}},{"facility":"Research Site","city":"Orbassano","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Research Site","city":"Orbassano","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Research Site","city":"Palermo","zip":"90126","country":"Italy","geoPoint":{"lat":38.1166,"lon":13.3636}},{"facility":"Research Site","city":"Palermo","country":"Italy","geoPoint":{"lat":38.1166,"lon":13.3636}},{"facility":"Research Site","city":"Torino","zip":"10126","country":"Italy","geoPoint":{"lat":44.88856,"lon":11.99138}},{"facility":"Research Site","city":"Torino","country":"Italy","geoPoint":{"lat":44.88856,"lon":11.99138}},{"facility":"Research Site","city":"Coimbra","zip":"3040-316","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"Research Site","city":"Coimbra","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"Research Site","city":"Lisbon","zip":"1649-035","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Research Site","city":"Lisbon","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"Research Site","city":"Porto","zip":"4200-072","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Research Site","city":"Porto","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Research Site","city":"Vila Nova de Gaia","zip":"4430-502","country":"Portugal","geoPoint":{"lat":41.12401,"lon":-8.61241}},{"facility":"Research Site","city":"Vila Nova de Gaia","country":"Portugal","geoPoint":{"lat":41.12401,"lon":-8.61241}}]},"referencesModule":{"seeAlsoLinks":[{"label":"AmgenTrials clinical trials website","url":"http://www.amgentrials.com"}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Participants were enrolled from 28 December 2006 through 11 August 2008.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"FG001","title":"Romiplostim 250 µg","description":"Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"FG002","title":"Romiplostim 500 µg","description":"Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"FG003","title":"Romiplostim 750 µg","description":"Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"17"}]},{"type":"Received Study Drug","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"16"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"16"},{"groupId":"FG003","numSubjects":"13"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Ineligibility determined","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Protocol deviation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Requirement for alternative therapy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo","description":"Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"BG001","title":"Romiplostim 250 µg","description":"Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"BG002","title":"Romiplostim 500 µg","description":"Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"BG003","title":"Romiplostim 750 µg","description":"Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"63"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.8","spread":"6.6"},{"groupId":"BG001","value":"63.8","spread":"10.8"},{"groupId":"BG002","value":"62.5","spread":"7.7"},{"groupId":"BG003","value":"65.4","spread":"8.2"},{"groupId":"BG004","value":"63.1","spread":"8.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"18"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"45"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"White or Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"62"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"This summary includes all treatment-emergent adverse events recorded from the start of investigational product on this study, or any worsening of adverse events initially experienced before initiation of this study.","populationDescription":"Safety Analysis Set, composed of all randomized participants who received at least one dose of study medication.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"4 months","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG001","title":"Romiplostim 250 µg","description":"Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG002","title":"Romiplostim 500 µg","description":"Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG003","title":"Romiplostim 750 µg","description":"Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"14"}]}]}]},{"type":"SECONDARY","title":"Duration of Grade 3 or 4 Thrombocytopenia","description":"The duration of grade 3 or 4 thrombocytopenia (defined as platelet count \\<50 x 10\\^9/L) experienced during the first on study chemotherapy cycle by treatment group.","populationDescription":"Efficacy Analysis Set, composed of all randomized participants except those who were replaced (participants who discontinued prior to the completion of at least 1 romiplostim treatment cycle for non-platelet-related reasons).","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days","timeFrame":"3 weeks","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG001","title":"Romiplostim 250 µg","description":"Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG002","title":"Romiplostim 500 µg","description":"Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG003","title":"Romiplostim 750 µg","description":"Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"3.3"},{"groupId":"OG001","value":"3.6","spread":"4.3"},{"groupId":"OG002","value":"2.6","spread":"3.9"},{"groupId":"OG003","value":"2.1","spread":"2.7"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.972","statisticalMethod":"Satterthwaite t-test"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.725","statisticalMethod":"Satterthwaite t-test"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.312","statisticalMethod":"Satterthwaite t-test"}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Grade 3 or 4 Thrombocytopenia During the First Treatment Cycle.","description":"The number of participants in each treatment group with grade 3 or 4 thrombocytopenia during the first on study treatment cycle. Per the Common Terminology Criteria for Adverse Events (CTCAE) v3.0, participants with a platelet count \\< 50 x 10\\^9/L, but ≥ 25 x 10\\^9/L are considered to have Grade 3 thrombocytopenia and participants with a platelet count \\< 25 x 10\\^9/L are considered to have Grade 4 thrombocytopenia. Additionally, participants with a platelet transfusion during the first on-study treatment cycle were classified as having Grade 3/4 thrombocytopenia.","populationDescription":"Efficacy Analysis Set, composed of all randomized participants except those who were replaced.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"3 weeks","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG001","title":"Romiplostim 250 µg","description":"Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG002","title":"Romiplostim 500 µg","description":"Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG003","title":"Romiplostim 750 µg","description":"Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.000","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.000","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.000","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Number of Participants With Platelet Transfusions","description":"Number of participants who were administered platelet transfusions during first on study treatment cycle.","populationDescription":"Efficacy Analysis Set, composed of all randomized participants except those who were replaced.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"3 weeks","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG001","title":"Romiplostim 250 µg","description":"Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG002","title":"Romiplostim 500 µg","description":"Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG003","title":"Romiplostim 750 µg","description":"Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.000","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.000","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.342","statisticalMethod":"Fisher Exact"}]},{"type":"SECONDARY","title":"Platelet Count on Day 22","description":"Platelet count on Day 22 of the first on study chemotherapy treatment cycle (planned Day 1 of next cycle) by treatment group","populationDescription":"Efficacy Analysis Set, composed of all randomized participants except those who were replaced","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9/L","timeFrame":"Day 22","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG001","title":"Romiplostim 250 µg","description":"Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG002","title":"Romiplostim 500 µg","description":"Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG003","title":"Romiplostim 750 µg","description":"Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"281.2","spread":"116.0"},{"groupId":"OG001","value":"222.6","spread":"112.0"},{"groupId":"OG002","value":"412.8","spread":"295.2"},{"groupId":"OG003","value":"336.0","spread":"254.9"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.454","statisticalMethod":"Satterthwaite t-test"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.101","statisticalMethod":"Satterthwaite t-test"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.199","statisticalMethod":"Satterthwaite t-test"}]},{"type":"SECONDARY","title":"Gemcitabine Dose Reduction on Day 8 of the First Chemotherapy Cycle","description":"Number of participants who required a gemcitabine dose reduction on Day 8 of the first on study chemotherapy cycle.","populationDescription":"Efficacy Analysis Set, composed of all randomized participants except those who were replaced.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"8 days","groups":[{"id":"OG000","title":"Placebo","description":"Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG001","title":"Romiplostim 250 µg","description":"Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG002","title":"Romiplostim 500 µg","description":"Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."},{"id":"OG003","title":"Romiplostim 750 µg","description":"Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"}]}]}],"analyses":[{"groupIds":["OG000","OG003"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.662","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"1.000","statisticalMethod":"Fisher Exact"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.662","statisticalMethod":"Fisher Exact"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From signing of the informed consent through 30 days after the last dose of investigational product or end of study, whichever is longer (up to 4 months).","description":"The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.","seriousNumAffected":1,"seriousNumAtRisk":12,"otherNumAffected":12,"otherNumAtRisk":12},{"id":"EG001","title":"Romiplostim 250 µg","description":"Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.","seriousNumAffected":7,"seriousNumAtRisk":16,"otherNumAffected":16,"otherNumAtRisk":16},{"id":"EG002","title":"Romiplostim 500 µg","description":"Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.","seriousNumAffected":5,"seriousNumAtRisk":18,"otherNumAffected":17,"otherNumAtRisk":18},{"id":"EG003","title":"Romiplostim 750 µg","description":"Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.","seriousNumAffected":5,"seriousNumAtRisk":16,"otherNumAffected":14,"otherNumAtRisk":16}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":3,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Cyanosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Retinal artery occlusion","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Catheter related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":2,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":12},{"groupId":"EG001","numAffected":7,"numAtRisk":16},{"groupId":"EG002","numAffected":7,"numAtRisk":18},{"groupId":"EG003","numAffected":5,"numAtRisk":16}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Granulocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":2,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Hypercoagulation","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":16},{"groupId":"EG002","numAffected":4,"numAtRisk":18},{"groupId":"EG003","numAffected":2,"numAtRisk":16}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":3,"numAtRisk":16},{"groupId":"EG002","numAffected":3,"numAtRisk":18},{"groupId":"EG003","numAffected":5,"numAtRisk":16}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Thrombocythaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":12},{"groupId":"EG001","numAffected":8,"numAtRisk":16},{"groupId":"EG002","numAffected":8,"numAtRisk":18},{"groupId":"EG003","numAffected":8,"numAtRisk":16}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Ear disorder","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Eyelid oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Abdominal tenderness","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":2,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":2,"numAtRisk":16}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":16},{"groupId":"EG002","numAffected":5,"numAtRisk":18},{"groupId":"EG003","numAffected":2,"numAtRisk":16}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Retching","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Catheter site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Catheter site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":5,"numAtRisk":16},{"groupId":"EG002","numAffected":4,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Infusion site extravasation","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Local swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Localised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":2,"numAtRisk":16}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":5,"numAtRisk":16},{"groupId":"EG002","numAffected":2,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Hepatic pain","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Fungal oesophagitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Furuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":2,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Excoriation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Radiation injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Transfusion reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Blood potassium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Platelet count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":16},{"groupId":"EG002","numAffected":3,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Muscle fatigue","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":2,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":3,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":3,"numAtRisk":18},{"groupId":"EG003","numAffected":3,"numAtRisk":16}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Burning sensation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Restlessness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Nocturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Renal pain","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":2,"numAtRisk":18},{"groupId":"EG003","numAffected":4,"numAtRisk":16}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":16},{"groupId":"EG002","numAffected":3,"numAtRisk":18},{"groupId":"EG003","numAffected":2,"numAtRisk":16}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":3,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":2,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":1,"numAtRisk":16}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":3,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Increased tendency to bruise","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":2,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Scab","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Skin disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Phlebitis superficial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":16},{"groupId":"EG002","numAffected":1,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":16},{"groupId":"EG002","numAffected":0,"numAtRisk":18},{"groupId":"EG003","numAffected":0,"numAtRisk":16}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication."},"pointOfContact":{"title":"Study Director","organization":"Amgen Inc.","phone":"866-572-6436"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D008175","term":"Lung Neoplasms"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D009369","term":"Neoplasms"},{"id":"D013921","term":"Thrombocytopenia"}],"ancestors":[{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D001791","term":"Blood Platelet Disorders"},{"id":"D006402","term":"Hematologic Diseases"},{"id":"D006425","term":"Hemic and Lymphatic Diseases"},{"id":"D000095542","term":"Cytopenia"}]},"interventionBrowseModule":{"meshes":[{"id":"C488777","term":"romiplostim"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D016190","term":"Carboplatin"},{"id":"D002945","term":"Cisplatin"}],"ancestors":[{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"}]}},"hasResults":true}